Clinical Trial Update: Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating the combination of rituximab and liposomal doxorubicin in relapsed or refractory non-Hodgkin lymphoma across Phase 1 and Phase 2; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Rituximab (rituximab)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-07-14